We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Nicox Sa | LSE:0RCQ | London | Ordinary Share | FR0013018124 | NICOX ORD SHS |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 5.67 | 5.53 | 5.81 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 4.03M | -27.76M | -0.5541 | -0.67 | 18.54M |
From May 2023 to May 2024
| Press Release |
| Nicox: Half-year liquidity contract statement with Kepler Cheuvreux |
July 11, 2023 – release at 7:30 am CET Sophia Antipolis, France
Under the liquidity contract entered into between Nicox and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30, 2023:
As a reminder:
The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.
| Buy Side | Sell Side | ||||||
| Number of executions | Number of shares | Traded volume in EUR | Number of executions | Number of shares | Traded volume in EUR | ||
| Total | 128 | 74 584 | 62 919.32 | 128 | 74 584 | 62 919.32 | |
| 02/01/2023 | - | - | - | 4 | 2 170 | 2 517.20 | |
| 03/01/2023 | - | - | - | 5 | 957 | 1 119.69 | |
| 04/01/2023 | 1 | 1 000 | 1 140.00 | 1 | 1 | 1.18 | |
| 06/01/2023 | 2 | 2 000 | 2 220.00 | - | - | - | |
| 09/01/2023 | - | - | - | 1 | 1 | 1.14 | |
| 10/01/2023 | 1 | 1 000 | 1 100.00 | - | - | - | |
| 11/01/2023 | - | - | - | 6 | 2 000 | 2 220.00 | |
| 12/01/2023 | 1 | 1 000 | 1 100.00 | 13 | 5 606 | 6 390.84 | |
| 13/01/2023 | 1 | 1 000 | 1 120.00 | 3 | 938 | 1 069.32 | |
| 16/01/2023 | 3 | 1 500 | 1 665.00 | 1 | 1 000 | 1 130.00 | |
| 17/01/2023 | 1 | 1 000 | 1 100.00 | - | - | - | |
| 18/01/2023 | 4 | 2 000 | 2 200.00 | 1 | 2 000 | 2 240.00 | |
| 19/01/2023 | 3 | 2 000 | 2 180.00 | - | - | - | |
| 20/01/2023 | 3 | 2 001 | 2 141.07 | - | - | - | |
| 23/01/2023 | 7 | 2 999 | 3 148.95 | - | - | - | |
| 25/01/2023 | 6 | 4 000 | 3 920.00 | - | - | - | |
| 26/01/2023 | - | - | - | 2 | 2 005 | 2 005.00 | |
| 27/01/2023 | 6 | 4 000 | 3 920.00 | 4 | 2 000 | 2 040.00 | |
| 30/01/2023 | 2 | 1 500 | 1 485.00 | - | - | - | |
| 31/01/2023 | 1 | 500 | 495.00 | - | - | - | |
| 01/02/2023 | 1 | 1 000 | 990.00 | - | - | - | |
| 02/02/2023 | 2 | 1 500 | 1 470.00 | - | - | - | |
| 03/02/2023 | 1 | 1 000 | 960.00 | - | - | - | |
| 06/02/2023 | 3 | 1 500 | 1 410.00 | - | - | - | |
| 07/02/2023 | 1 | 1 000 | 930.00 | - | - | - | |
| 08/02/2023 | 1 | 500 | 460.00 | - | - | - | |
| 09/02/2023 | 2 | 1 000 | 900.00 | - | - | - | |
| 13/02/2023 | - | - | - | 7 | 4 000 | 3 600.00 | |
| 14/02/2023 | 1 | 1 000 | 890.00 | - | - | - | |
| 15/02/2023 | 1 | 1 000 | 880.00 | - | - | - | |
| 17/02/2023 | 1 | 500 | 430.00 | 1 | 100 | 87.00 | |
| 20/02/2023 | 1 | 50 | 43.00 | 4 | 4 900 | 4 263.00 | |
| 23/02/2023 | 1 | 50 | 42.50 | - | - | - | |
| 24/02/2023 | 2 | 1 020 | 846.60 | - | - | - | |
| 27/02/2023 | 5 | 1 900 | 1 558.00 | - | - | - | |
| 28/02/2023 | 1 | 500 | 400.00 | 4 | 2 000 | 1 640.00 | |
| 01/03/2023 | 3 | 1 964 | 1 571.20 | 1 | 2 000 | 1 620.00 | |
| 02/03/2023 | 2 | 1 000 | 800.00 | - | - | - | |
| 03/03/2023 | - | - | - | 2 | 504 | 403.20 | |
| 06/03/2023 | 1 | 1 000 | 790.00 | - | - | - | |
| 07/03/2023 | 2 | 1 500 | 1 185.00 | - | - | - | |
| 08/03/2023 | 4 | 1 500 | 1 185.00 | - | - | - | |
| Buy Side | Sell Side | ||||||
| Number of executions | Number of shares | Traded volume in EUR | Number of executions | Number of shares | Traded volume in EUR | ||
| Total | 128 | 74 584 | 62 919.32 | 128 | 74 584 | 62 919.32 | |
| 09/03/2023 | 2 | 1 000 | 780.00 | - | - | - | |
| 10/03/2023 | 2 | 500 | 380.00 | - | - | - | |
| 13/03/2023 | 1 | 500 | 375.00 | - | - | - | |
| 15/03/2023 | 1 | 500 | 350.00 | - | - | - | |
| 17/03/2023 | 1 | 300 | 198.00 | - | - | - | |
| 20/03/2023 | 1 | 200 | 128.00 | 1 | 77 | 50.82 | |
| 21/03/2023 | - | - | - | 1 | 123 | 81.18 | |
| 29/03/2023 | 1 | 300 | 180.00 | - | - | - | |
| 14/04/2023 | - | - | - | 25 | 12 800 | 10 368.00 | |
| 17/04/2023 | 5 | 1 800 | 1 260.00 | - | - | - | |
| 18/04/2023 | - | - | - | 3 | 600 | 438.00 | |
| 19/04/2023 | 9 | 4 000 | 2 520.00 | - | - | - | |
| 20/04/2023 | 2 | 1 300 | 767.00 | - | - | - | |
| 21/04/2023 | 3 | 1 000 | 580.00 | - | - | - | |
| 25/04/2023 | 2 | 1 000 | 550.00 | - | - | - | |
| 26/04/2023 | - | - | - | 9 | 4 200 | 2 688.00 | |
| 02/05/2023 | - | - | - | 2 | 500 | 325.00 | |
| 04/05/2023 | 1 | 300 | 180.00 | - | - | - | |
| 09/05/2023 | 1 | 1 000 | 580.00 | 2 | 4 000 | 2 400.00 | |
| 10/05/2023 | 3 | 2 500 | 1 475.00 | - | - | - | |
| 12/05/2023 | 1 | 1 000 | 590.00 | 3 | 2 000 | 1 200.00 | |
| 15/05/2023 | 1 | 1 000 | 600.00 | - | - | - | |
| 16/05/2023 | 2 | 2 000 | 1 160.00 | - | - | - | |
| 17/05/2023 | - | - | - | 4 | 2 000 | 1 180.00 | |
| 25/05/2023 | 2 | 2 000 | 1 160.00 | - | - | - | |
| 29/05/2023 | 5 | 3 000 | 1 710.00 | - | - | - | |
| 01/06/2023 | - | - | - | 1 | 500 | 290.00 | |
| 06/06/2023 | 1 | 300 | 165.00 | - | - | - | |
| 20/06/2023 | 1 | 500 | 255.00 | - | - | - | |
| 21/06/2023 | 2 | 600 | 300.00 | - | - | - | |
| About Nicox | ||
| Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470, a novel nitric oxide-donating bimatoprost, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company is also conducting research on NCX 1728, a nitric oxide-donating phosphodiesterase 5 inhibitor, in retinal conditions. NCX 4251, a novel, patented, ophthalmic suspension of fluticasone propionate nanocrystals for topical ocular application for dry eye disease, is being developed by Ocumension Therapeutics in China under an exclusive license agreement and is available for partnering elsewhere. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC (a wholly owned subsidiary of Santen Pharmaceutical Co., Ltd.), in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index.For more information on Nicox, its products or pipeline, please visit: www.nicox.com. | ||
| Analyst coverage | ||
| Bryan, Garnier & Co Eric Yoo Paris, FranceEdison Investment Research Pooya Hemami London, UKH.C. Wainwright & Co Yi Chen New York, U.S.Kepler Cheuvreux Arsene Guekam Paris, France | ||
| The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. | ||
| Contacts | ||
| NicoxGavin SpencerExecutive Vice President, Chief Business Officer& Head of Corporate Development T +33 (0)4 97 24 53 00communications@nicox.com | ||
| Forward-Looking Statements | ||
| The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.Risks factors which are likely to have a material effect on Nicox’s business are presented in section 2.7 of the ‘Rapport Annuel 2022’ which is available on Nicox’s website (www.nicox.com). | ||
| Nicox SADrakkar 2 - Bât D2405 route des Dolines06560 Valbonne, FranceT +33 (0)4 97 24 53 00F +33 (0)4 97 24 53 99 | ||
Attachment
1 Year Nicox Chart |
1 Month Nicox Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
